Walter Mier

This inventor holds 22 USPTO granted patents and 19 published patent applications, plus 5 CIPO patents and 16 EPO patents. Top assignees: Ruprecht-Karls-Universitat Heidelberg, Merck Patent Gmbh, Deutsches Krebsforschungszentrum. Active years: 2002-2024.

USPTO Granted Patents = 22 (Patent Applications = 19)

% Patents Active = 90.9

CIPO Patents = 5 (Patent Applications = 4)

EPO Patents = 16 (Patent Applications = 35)

Average Co-Inventor Count = 4.5

ph-index = 5

Forward Citations = 86(Granted Patents)

Location History:

Dossenheim, DE (2002)
Heidelberg, DE (2002 - 2005)
Bensheim, DE (2015 - 2024)

Company Filing History:

9 out of 63

Ruprecht-Karls-Universitat Heidelberg

Deutsches Krebsforschungszentrum

patents

4. 3 out of 166

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Universitat Heidelberg

Ruprecht-Karls-Universität

patents

9. 1 out of 1

Ruprecht-Karls-Universität-Heidelberg (Rektorat)

patent

where one patent can have more than one assignee

Years Active: 2002-2024

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11951190 - Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer (2024-04-09),

2. 11931430 - Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer (2024-03-19),

3. 11401304 - Cyclic NTCP-targeting peptides and their uses as entry inhibitors (2022-08-02),

4. 11202833 - Methylglyoxal-scavenging cyclic peptides and their use for the prevention and treatment of diseases associated with elevated methylglyoxal levels (2021-12-21),

5. 11045564 - Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer (2021-06-29),

6. 10716757 - Liposomal formulation for the oral hepatic delivery of drugs (2020-07-21),

7. 10703796 - CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases (2020-07-07),

8. 10653796 - Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules (2020-05-19),

9. 10513539 - Hydrophobic modified peptides and their use for liver specific targeting (2019-12-24),

10. 10471160 - Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer (2019-11-12),

11. 10413614 - Conjugates for protection from nephrotoxic active substances (2019-09-17),

12. 10398791 - Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer (2019-09-03),

13. 10363323 - Hydrophobic modified peptides for liver specific diagnosis (2019-07-30),

14. 10253099 - Conjugates of proteins and multivalent cell-penetrating peptides and their uses (2019-04-09),

15. 10065993 - Peptides and peptide/active compound conjugates for renal targeting (2018-09-04),

Title: Walter Mier - Innovative Inventor from Bensheim

Introduction: Walter Mier is a renowned inventor hailing from Bensheim, Germany, known for his groundbreaking contributions to various fields of technology and science.

Latest Patents: Walter Mier holds several patents in the areas of renewable energy, sustainable materials, and advanced robotics, showcasing his commitment to creating solutions for the future.

Career Highlights: With a career spanning over two decades, Walter Mier has worked with leading research institutions and universities to develop cutting-edge technologies that have revolutionized industries worldwide.

Collaborations: Throughout his career, Walter Mier has collaborated with top companies, innovative startups, and brilliant minds in the field, fostering a culture of creativity and innovation.

Conclusion: Walter Mier's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the landscape of technological advancements globally.